Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Zafari J et al. | 2015 | intact cell/cell culture, HeLa cell line (human adenocarcinoma cell line) and fibroblasts | static magnetic field, DC | 5–30 mT |
Schwenzer NF et al. | 2007 | intact cell/cell culture, Hel 299 (human fibroblast cell line) | static magnetic field, magnetic field, MRI | - |
Song C et al. | 2021 | intact cell/cell culture, IOSE 386 (normal human ovarian cells), SKOV 3 and HO 8910 (ovarian carcinoma cells), animal, mouse/BALB/c (nude mice), whole body | static magnetic field | - |
Esformes I et al. | 1981 | intact cell/cell culture, JY human lymphocytes, WI-18 human embryonic fibroblasts, LM mouse embryo fibroblast, animal, rat | static magnetic field | 50 mT |
Ghibelli L et al. | 2006 | intact cell/cell culture, Jurkat cells (human lymphoblastoid T cells) and U937 (human leukemic monocyte cell line) | static magnetic field, MRI, therapeutic/medical device | 6 mT–1 T |
Aldinucci C et al. | 2003 | intact cell/cell culture, Jurkat cells (human lymphoblastoid T cells) and human lymphocytes | static magnetic field, MRI | 4.75 T |
Aldinucci C et al. | 2003 | intact cell/cell culture, Jurkat cells (human lymphoblastoid T cells) and human lymphocytes | RF, static magnetic field, MRI | 0.7 mT–4.75 T |
Chen WF et al. | 2010 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) | static magnetic field, co-exposure | 8.8 mT |
Sun RG et al. | 2012 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) | static magnetic field | 8.8 mT |
Zhao B et al. | 2021 | intact cell/cell culture, K7M2 (murine osteosarcoma cell line), MG63 (human osteosarcoma cell line), animal, mouse/BALB/c with injected K7M2 osteosarcoma stem cells | static magnetic field | - |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.